PcBaSe Sweden

Orrason AW, Styrke J, Garmo H, Stattin P. Evidence of cancer progression as the cause of death in men with prostate cancer in Sweden. BJU Int. 2023;131(4):486-93.
DOI: https://doi.org/10.1111/bju.15891
SwePub: oai:DiVA.org:umu-200119

Westerberg M. Estimation in discrete time coarsened multivariate longitudinal models. Stat Methods Med Res. 2023;32(4):806-19.
DOI: https://doi.org/10.1177/09622802231155010
SwePub: oai:DiVA.org:uu-469825

Tomic K, Sandin F, Wigertz A, Robinson D, Lambe M, Stattin P. Evaluation of data quality in the National Prostate Cancer Register of Sweden. Eur J Cancer. 2015;51(1):101-11.
DOI: https://doi.org/10.1016/j.ejca.2014.10.025
SwePub: oai:DiVA.org:umu-97301

Cazzaniga W, Godtman RA, Carlsson S, Ahlgren G, Johansson E, Robinson D, et al. Population-based, nationwide registration of prostatectomies in Sweden. J Surg Oncol. 2019;120(4):803-12.
DOI: https://doi.org/10.1002/jso.25643
SwePub: oai:gup.ub.gu.se/282793

Loeb S, Folkvaljon Y, Bratt O, Robinson D, Stattin P. Defining intermediate risk prostate cancer suitable for active surveillance. J Urol. 2019;201(2):292-9.
DOI: https://doi.org/10.1016/j.juro.2018.09.042
SwePub: oai:DiVA.org:uu-375806

Robinson D, Garmo H, Van Hemelrijck M, Damber JE, Bratt O, Holmberg L, et al. Androgen deprivation therapy for prostate cancer and risk of dementia. BJU Int. 2019;124(1):87-92.
DOI: https://doi.org/10.1111/bju.14666
SwePub: oai:gup.ub.gu.se/281861

Bonde Miranda T, Garmo H, Stattin P, Robinson D. 5α-reductase inhibitors and risk of prostate cancer death. J Urol. 2020;204(4):714-9.
DOI: https://doi.org/10.1097/ju.0000000000001038
SwePub: oai:DiVA.org:uu-422799

Bratt O, Drevin L, Prütz KG, Carlsson S, Wennberg L, Stattin P. Prostate cancer in kidney transplant recipients - a nationwide register study. BJU Int. 2020;125(5):679-85.
DOI: https://doi.org/10.1111/bju.15002
SwePub: oai:gup.ub.gu.se/291260

Fallara G, Lissbrant IF, Styrke J, Montorsi F, Garmo H, Stattin P. Observational study on time on treatment with abiraterone and enzalutamide. PLoS One. 2020;15(12):e0244462.
DOI: https://doi.org/10.1371/journal.pone.0244462
SwePub: oai:gup.ub.gu.se/302513

Klein RJ, Vertosick E, Sjoberg D, Ulmert D, Rönn AC, Häggström C, et al. Prostate cancer polygenic risk score and prediction of lethal prostate cancer. NPJ Precis Oncol. 2022;6(1):25.
DOI: https://doi.org/10.1038/s41698-022-00266-8
SwePub: oai:DiVA.org:umu-194353

Jochems SHJ, Fritz J, Häggström C, Järvholm B, Stattin P, Stocks T. Smoking and risk of prostate cancer and prostate cancer death: a pooled study. Eur Urol. 2023;83(5):422-31.
DOI: https://doi.org/10.1016/j.eururo.2022.03.033
SwePub: oai:DiVA.org:umu-194908

Ventimiglia E, Gedeborg R, Styrke J, Robinson D, Stattin P, Garmo H. Natural history of nonmetastatic prostate cancer managed with watchful waiting. JAMA Netw Open. 2024;7(6):e2414599.
DOI: https://doi.org/10.1001/jamanetworkopen.2024.14599
SwePub: oai:DiVA.org:umu-225966

Bonn SE, Sjölander A, Lagerros YT, Wiklund F, Stattin P, Holmberg E, et al. Physical activity and survival among men diagnosed with prostate cancer. Cancer Epidemiol Biomarkers Prev. 2015;24(1):57-64.
DOI: https://doi.org/10.1158/1055-9965.Epi-14-0707
SwePub: oai:DiVA.org:umu-100146

Tomic K, Berglund A, Robinson D, Hjälm-Eriksson M, Carlsson S, Lambe M, et al. Capture rate and representativity of The National Prostate Cancer Register of Sweden. Acta Oncol. 2015;54(2):158-63.
DOI: https://doi.org/10.3109/0284186x.2014.939299
SwePub: oai:DiVA.org:umu-94131

Wilson KM, Markt SC, Fang F, Nordenvall C, Rider JR, Ye W, et al. Snus use, smoking and survival among prostate cancer patients. Int J Cancer. 2016;139(12):2753-9.
DOI: https://doi.org/10.1002/ijc.30411
SwePub: oai:DiVA.org:uu-336250

Van Hemelrijck M, Folkvaljon Y, Adolfsson J, Akre O, Holmberg L, Garmo H, et al. Causes of death in men with localized prostate cancer: a nationwide, population-based study. BJU Int. 2016;117(3):507-14.
DOI: https://doi.org/10.1111/bju.13059
SwePub: oai:DiVA.org:umu-117803

Robertson S, Adolfsson J, Stattin P, Sjövall A, Winnersjö R, Hanning M, et al. Waiting times for cancer patients in Sweden: a nationwide population-based study. Scand J Public Health. 2017;45(3):230-7.
DOI: https://doi.org/10.1177/1403494817693695
SwePub: oai:DiVA.org:uu-322713

Li W, Middha M, Bicak M, Sjoberg DD, Vertosick E, Dahlin A, et al. Genome-wide scan identifies role for AOX1 in prostate cancer survival. Eur Urol. 2018;74(6):710-9.
DOI: https://doi.org/10.1016/j.eururo.2018.06.021
SwePub: oai:lup.lub.lu.se:8738fe3a-aa6e-4aee-a5c0-5e4b81155eb4

Stattin P, Franck Lissbrant I. Diagnosspecifika översikter är viktiga verktyg för cancervården. Läkartidningen. 2018;115;EYFW.
URN: urn:nbn:se:uu:diva-440131
SwePub: oai:DiVA.org:uu-440131

Hagel E, Garmo H, Bill-Axelson A, Bratt O, Johansson JE, Adolfsson J, Lambe M, Stattin P. PCBaSe Sweden: a register-based resource for prostate cancer research. Scand J Urol Nephrol. 2009;43(5):342-9.
DOI: https://doi.org/10.3109/00365590903024577
SwePub: urn:nbn:se:oru:diva-11781

Van Hemelrijck M, Drevin L, Holmberg L, Garmo H, Adolfsson J, Stattin P. Primary cancers before and after prostate cancer diagnosis. Cancer. 2012;118(24):6207-16.
DOI: https://doi.org/10.1002/cncr.27672
SwePub: urn:nbn:se:umu:diva-64959

Van Hemelrijck M, Garmo H, Michaëlsson K, Thorstenson A, Akre O, Stattin P, et al. Mortality following hip fracture in men with prostate cancer. PLoS One. 2013;8(9):e74492.
DOI: https://doi.org/10.1371/journal.pone.0074492
SwePub: urn:nbn:se:umu:diva-83102

Wirén S, Drevin L, Akre O, Robinson D, Stattin P. Fathering of dizygotic twins and risk of prostate cancer: nationwide, population-based case-control study. PLoS One. 2014;9(10):e110506.
DOI: https://doi.org/10.1371/journal.pone.0110506
SwePub: oai:DiVA.org:uu-306324

Plym A, Chiesa F, Voss M, Holmberg L, Johansson E, Stattin P, et al. Work disability after robot-assisted or open radical prostatectomy: a nationwide, population-based study. Eur Urol. 2016;70(1):64-71.
DOI: https://doi.org/10.1016/j.eururo.2015.12.049
SwePub: oai:DiVA.org:uu-298833

Ladjevardi S, Sandblom G, Berglund A, Varenhorst E. Tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer. Eur Urol. 2010;57(4):631-8.
DOI: https://doi.org/10.1016/j.eururo.2009.03.007
SwePub: urn:nbn:se:uu:diva-136812

Bratt O, Garmo H, Adolfsson J, Bill-Axelson A, Holmberg L, Lambe M, et al. Effects of prostate-specific antigen testing on familial prostate cancer risk estimates. J Natl Cancer Inst. 2010 Sep 8;102(17):1336-43.
DOI: https://doi.org/10.1093/jnci/djq265
SwePub: urn:nbn:se:umu:diva-42221

Damber JE. Words of wisdom. RE: Use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma. Eur Urol. 2015;68(6):1102.
DOI: https://doi.org/10.1016/j.eururo.2015.08.051
SwePub: oai:gup.ub.gu.se/226905

Danneman D, Drevin L, Robinson D, Stattin P, Egevad L. Gleason inflation 1998-2011: a registry study of 97,168 men. BJU Int. 2015;115(2):248-55.
DOI: https://doi.org/10.1111/bju.12671
SwePub: oai:DiVA.org:umu-100281

Stattin P. Mortality in older men with low-risk prostate cancer and high comorbidity. J Clin Oncol. 2015;33(9):1086-7.
DOI: https://doi.org/10.1200/jco.2014.58.2536
SwePub: oai:DiVA.org:umu-106339

O'Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2015;33(11):1243-51.
DOI: https://doi.org/10.1200/jco.2014.59.1792
SwePub: oai:DiVA.org:uu-258548

Bratt O, Folkvaljon Y, Hjälm Eriksson M, Akre O, Carlsson S, Drevin L, et al. Undertreatment of men in their seventies with high-risk nonmetastatic prostate cancer. Eur Urol. 2015;68(1):53-8.
DOI: https://doi.org/10.1016/j.eururo.2014.12.026
SwePub: oai:DiVA.org:uu-257629

Loeb S, Folkvaljon Y, Lambe M, Robinson D, Garmo H, Ingvar C, et al. Use of Phosphodiesterase Type 5 inhibitors for erectile dysfunction and risk of malignant melanoma. JAMA. 2015;313(24):2449-55.
DOI: https://doi.org/10.1001/jama.2015.6604
SwePub: oai:DiVA.org:uu-258329

Fridriksson JÖ, Folkvaljon Y, Lundström KJ, Robinson D, Carlsson S, Stattin P. Long-term adverse effects after retropubic and robot-assisted radical prostatectomy. Nationwide, population-based study. J Surg Oncol. 2017;116(4):500-6.
DOI: https://doi.org/10.1002/jso.24687
SwePub: oai:DiVA.org:umu-140946

Häggström C, Van Hemelrijck M, Zethelius B, Robinson D, Grundmark B, Holmberg L, et al. Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer. Int J Cancer. 2017;140(3):611-7.
DOI: https://doi.org/10.1002/ijc.30480
SwePub: oai:gup.ub.gu.se/260469

Van Hemelrijck M, Adolfsson J, Garmo H, Bill-Axelson A, Bratt O, Ingelsson E, Lambe M, Stattin P, Holmberg L. Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden. Lancet Oncol. 2010 May;11(5):450-8.
DOI: https://doi.org/10.1016/s1470-2045(10)70038-3
SwePub: urn:nbn:se:umu:diva-42202

Carlsson S, Bratt O, Stattin P, Egevad L. Current routines for transrectal ultrasound-guided prostate biopsy: a web-based survey by the Swedish Urology Network. Scand J Urol Nephrol. 2012;46(6):405-10.
DOI: https://doi.org/10.3109/00365599.2012.691111
SwePub: urn:nbn:se:umu:diva-63023

Plym A, Folkvaljon Y, Garmo H, Holmberg L, Johansson E, Fransson P, et al. Drug prescription for erectile dysfunction before and after diagnosis of localized prostate cancer. J Sex Med. 2014;11(8):2100-8.
DOI: https://doi.org/10.1111/jsm.12586
SwePub: urn:nbn:se:umu:diva-93231

Lundström KJ, Drevin L, Carlsson S, Garmo H, Loeb S, Stattin P, et al. Nationwide population based study of infections after transrectal ultrasound guided prostate biopsy. J Urol. 2014;192(4):1116-22.
DOI: https://doi.org/10.1016/j.juro.2014.04.098
SwePub: urn:nbn:se:uu:diva-235158

Grotta A, Bottai M, Adami HO, Adams SA, Akre O, Blair SN, et al. Physical activity and body mass index as predictors of prostate cancer risk. World J Urol. 2015;33(10):1495-502.
DOI: https://doi.org/10.1007/s00345-014-1464-5
SwePub: oai:DiVA.org:umu-121211

Robinson D, Garmo H, Stattin P, Michaëlsson K. Risk of fractures and falls during and after 5-α reductase inhibitor use: a nationwide cohort study. PLoS One. 2015;10(10):e0140598.
DOI: https://doi.org/10.1371/journal.pone.0140598
SwePub: oai:DiVA.org:uu-266032

Loeb S, Lambe M, Stattin P. Re: Editorial comment on use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma: D. F. Penson J Urol 2015;194:1710-1711. J Urol. 2016;195(4 Pt 1):1172-3.
DOI: https://doi.org/10.1016/j.juro.2015.11.040
SwePub: oai:DiVA.org:uu-299083

Loeb S, Stattin P. Further evidence against a causal association between erectile dysfunction drugs and melanoma. Eur Urol. 2016;70(5):816-7.
DOI: https://doi.org/10.1016/j.eururo.2016.07.009
SwePub: oai:DiVA.org:uu-309473

Stattin P, Sandin F, Sandbäck T, Damber JE, Franck Lissbrant I, Robinson D, et al. Dashboard report on performance on select quality indicators to cancer care providers. Scand J Urol. 2016;50(1):21-8.
DOI: https://doi.org/10.3109/21681805.2015.1063083
SwePub: oai:DiVA.org:uu-275554

Lundström KJ, Folkvaljon Y, Loeb S, Axelson AB, Stattin P, Nordin P. Small bowel obstruction and abdominal pain after robotic versus open radical prostatectomy. Scand J Urol. 2016;50(3):155-9.
DOI: https://doi.org/10.3109/21681805.2016.1141319
SwePub: oai:DiVA.org:uu-297260

O'Farrell S, Sandström K, Garmo H, Stattin P, Holmberg L, Adolfsson J, et al. Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy. BJU Int. 2016;118(3):391-8.
DOI: https://doi.org/10.1111/bju.13360
SwePub: oai:DiVA.org:umu-121207

Plym A, Voss M, Stattin P, Lambe M. Reply from authors re: Matthew T. Gettman. Assessing work disability after radical prostatectomy. Eur Urol 2016;70:72-3: The challenge of assessing work disability. Eur Urol. 2016;70(1):73-4.
DOI: https://doi.org/10.1016/j.eururo.2016.01.040
SwePub: oai:DiVA.org:uu-299764

Kristiansen A, Drevin L, Delahunt B, Samaratunga H, Robinson D, Franck Lissbrant I, et al. Prognostic significance and biopsy characteristics of prostate cancer with seminal vesicle invasion on radical prostatectomy: a nationwide population-based study. Pathology. 2017;49(7):715-20.
DOI: https://doi.org/10.1016/j.pathol.2017.08.008
SwePub: oai:DiVA.org:umu-142962

Thomsen FB, Sandin F, Garmo H, Lissbrant IF, Ahlgren G, Van Hemelrijck M, et al. Gonadotropin-releasing hormone agonists, orchiectomy, and risk of cardiovascular disease: semi-ecologic, nationwide, population-based study. Eur Urol. 2017;72(6):920-8.
DOI: https://doi.org/10.1016/j.eururo.2017.06.036
SwePub: oai:DiVA.org:uu-336238

Licciardello MP, Ringler A, Markt P, Klepsch F, Lardeau CH, Sdelci S, et al. A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor. Nat Chem Biol. 2017;13(7):771-8.
DOI: https://doi.org/10.1038/nchembio.2382
SwePub: oai:DiVA.org:umu-137623

Loeb S, Folkvaljon Y, Curnyn C, Robinson D, Bratt O, Stattin P. Uptake of active surveillance for very-low-risk prostate cancer in Sweden. JAMA Oncol. 2017;3(10):1393-8.
DOI: https://doi.org/10.1001/jamaoncol.2016.3600
SwePub: oai:DiVA.org:umu-141490

Arthur R, Møller H, Garmo H, Holmberg L, Stattin P, Malmstrom H, et al. Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories. Cancer Med. 2016;5(6):1307-18.
DOI: https://doi.org/10.1002/cam4.665
SwePub: oai:DiVA.org:umu-124521

Thomsen FB, Folkvaljon Y, Brasso K, Loeb S, Robinson D, Egevad L, et al. Prognostic implications of 2005 Gleason grade modification. Population-based study of biochemical recurrence following radical prostatectomy. J Surg Oncol. 2016;114(6):664-70.
DOI: https://doi.org/10.1002/jso.24408
SwePub: oai:DiVA.org:uu-309998

Loeb S, Folkvaljon Y, Damber JE, Alukal J, Lambe M, Stattin P. Testosterone replacement therapy and risk of favorable and aggressive prostate cancer. J Clin Oncol. 2017;35(13):1430-6.
DOI: https://doi.org/10.1200/jco.2016.69.5304
SwePub: oai:gup.ub.gu.se/253880

Bjartell A, Bottai M, Persson J, Bratt O, Damber JE, Stattin P, et al. Prediction of clinical progression after radical prostatectomy in a nationwide population-based cohort. Scand J Urol. 2016;50(4):255-9.
DOI: https://doi.org/10.1080/21681805.2016.1183226
SwePub: oai:gup.ub.gu.se/239654

Björklund J, Folkvaljon Y, Cole A, Carlsson S, Robinson D, Loeb S, et al. Postoperative mortality 90 days after robot-assisted laparoscopic prostatectomy and retropubic radical prostatectomy: a nationwide population-based study. BJU Int. 2016;118(2):302-6.
DOI: https://doi.org/10.1111/bju.13404
SwePub: oai:DiVA.org:uu-301011

Carlsson S, Drevin L, Loeb S, Widmark A, Lissbrant IF, Robinson D, et al. Population-based study of long-term functional outcomes after prostate cancer treatment. BJU Int. 2016;117(6b):E36-45.
DOI: https://doi.org/10.1111/bju.13179
SwePub: oai:DiVA.org:umu-103710

Crawley D, Garmo H, Rudman S, Stattin P, Häggström C, Zethelius B, et al. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer. Int J Cancer. 2016;139(12):2698-704.
DOI: https://doi.org/10.1002/ijc.30403
SwePub: oai:DiVA.org:uu-310736

Thomsen FB, Folkvaljon Y, Garmo H, Robinson D, Loeb S, Ingvar C, et al. Risk of malignant melanoma in men with prostate cancer: Nationwide, population-based cohort study. Int J Cancer. 2016;138(9):2154-60.
DOI: https://doi.org/10.1002/ijc.29961
SwePub: oai:DiVA.org:uu-282453

Tomic K, Westerberg M, Robinson D, Garmo H, Stattin P. Proportion and characteristics of men with unknown risk category in the National Prostate Cancer Register of Sweden. Acta Oncol. 2016;55(12):1461-6.
DOI: https://doi.org/10.1080/0284186x.2016.1234716
SwePub: oai:DiVA.org:umu-127328

Rajan P, Sooriakumaran P, Nyberg T, Akre O, Carlsson S, Egevad L, et al. Effect of comorbidity on prostate cancer-specific mortality: a prospective observational study. J Clin Oncol. 2017;35(31):3566-74.
DOI: https://doi.org/10.1200/jco.2016.70.7794
SwePub: oai:prod.swepub.kib.ki.se:136988446

Loeb S, Schlomm T, Stattin P. Associations do not equal causation: clinical relevance of statistical associations of phosphodiesterase type 5 inhibitors with prostate cancer progression and melanoma. Eur Urol. 2015;68(5):754-5.
DOI: https://doi.org/10.1016/j.eururo.2015.07.023
SwePub: oai:DiVA.org:umu-111463

Stattin P, Robinson D, Lambe M. Re: Giorgio Gandaglia, Freddie Bray, Matthew R. Cooperberg, et al. Prostate cancer registries: current status and future directions. Eur Urol 2015;68:e110. Eur Urol. 2015;68(5):e110.
DOI: https://doi.org/10.1016/j.eururo.2015.07.002
SwePub: oai:DiVA.org:umu-111464

Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst. 2010 Jul 7;102(13):950-8.
DOI: https://doi.org/10.1093/jnci/djq154
SwePub: urn:nbn:se:umu:diva-42210

Bill-Axelson A, Garmo H, Lambe M, Bratt O, Adolfsson J, Nyberg U, Steineck G, Stattin P. Suicide risk in men with prostate-specific antigen-detected early prostate cancer: a nationwide population-based cohort study from PCBaSe Sweden. Eur Urol. 2010 Mar;57(3):390-5.
DOI: https://doi.org/10.1016/j.eururo.2009.10.035
SwePub: urn:nbn:se:umu:diva-32693

Van Hemelrijck M, Wigertz A, Sandin F, Garmo H, Hellström K, Fransson P, et al. Cohort Profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. Int J Epidemiol. 2013;42(4):956-67.
DOI: https://doi.org/10.1093/ije/dys068
SwePub: urn:nbn:se:liu:diva-100498

Berglund A, Garmo H, Robinson D, Tishelman C, Holmberg L, Bratt O, et al. Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer. Eur J Cancer. 2012;48(1):75-84.
DOI: https://doi.org/10.1016/j.ejca.2011.07.009
SwePub: urn:nbn:se:umu:diva-48494

Robinson D, Garmo H, Lindahl B, Van Hemelrijck M, Adolfsson J, Bratt O, et al. Ischemic heart disease and stroke before and during endocrine treatment for prostate cancer in PCBaSe Sweden. Int J Cancer. 2012;130(2):478-87.
DOI: https://doi.org/10.1002/ijc.26022
SwePub: urn:nbn:se:umu:diva-48428

Akre O, Garmo H, Adolfsson J, Lambe M, Bratt O, Stattin P. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden. Eur Urol. 2011;60(3):554-63.
DOI: https://doi.org/10.1016/j.eururo.2011.05.047
SwePub: urn:nbn:se:umu:diva-46324

Holmström B, Holmberg E, Egevad L, Adolfsson J, Johansson JE, Hugosson J, et al. Outcome of primary versus deferred radical prostatectomy in the National Prostate Cancer Register of Sweden Follow-Up Study. J Urol. 2010;184(4):1322-7.
DOI: https://doi.org/10.1016/j.juro.2010.06.008
SwePub: urn:nbn:se:umu:diva-42197

Thorstenson A, Bratt O, Akre O, Hellborg H, Holmberg L, Lambe M, et al. Incidence of fractures causing hospitalisation in prostate cancer patients: results from the population-based PCBaSe Sweden. Eur J Cancer. 2012;48(11):1672-81.
DOI: https://doi.org/10.1016/j.ejca.2012.01.035
SwePub: urn:nbn:se:uu:diva-177850

Jansson KF, Akre O, Garmo H, Bill-Axelson A, Adolfsson J, Stattin P, et al. Concordance of tumor differentiation among brothers with prostate cancer. Eur Urol. 2012;62(4):656-61.
DOI: https://doi.org/10.1016/j.eururo.2012.02.032
SwePub: urn:nbn:se:uu:diva-181773

Van Hemelrijck M, Garmo H, Holmberg L, Stattin P, Adolfsson J. Multiple events of fractures and cardiovascular and thromboembolic disease following prostate cancer diagnosis: results from the population-based PCBaSe Sweden. Eur Urol. 2012;61(4):690-700.
DOI: https://doi.org/10.1016/j.eururo.2011.09.010
SwePub: urn:nbn:se:umu:diva-48503

Melvin JC, Garmo H, Daniel R, Shanmugalingam T, Stattin P, Häggström C, et al. An investigation into the relationship between statins and cancer using population-based data. BJU Int. 2015;116(5):681-3.
DOI: https://doi.org/10.1111/bju.12935
SwePub: oai:DiVA.org:uu-238797

Lindhagen L, Van Hemelrijck M, Robinson D, Stattin P, Garmo H. How to model temporal changes in comorbidity for cancer patients using prospective cohort data. BMC Med Inform Decis Mak. 2015;15:96.
DOI: https://doi.org/10.1186/s12911-015-0217-8
SwePub: oai:DiVA.org:uu-270447

Berglund A, Garmo H, Tishelman C, Holmberg L, Stattin P, Lambe M. Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden. J Urol. 2011;185(3):833-9.
DOI: https://doi.org/10.1016/j.juro.2010.10.061
SwePub: urn:nbn:se:umu:diva-42231

Bill-Axelson A, Garmo H, Nyberg U, Lambe M, Bratt O, Stattin P, et al. Psychiatric treatment in men with prostate cancer - results from a nation-wide, population-based cohort study from PCBaSe Sweden. Eur J Cancer. 2011;47(14):2195-201.
DOI: https://doi.org/10.1016/j.ejca.2011.04.022
SwePub: urn:nbn:se:umu:diva-48431

Stattin K, Sandin F, Bratt O, Lambe M. The risk of distant metastases and cancer specific survival in men with serum prostate specific antigen values above 100 ng/ml. J Urol. 2015;194(6):1594-600.
DOI: https://doi.org/10.1016/j.juro.2015.07.082
SwePub: oai:DiVA.org:uu-270951

Bratt O, Berglund A, Adolfsson J, Johansson JE, Törnblom M, Stattin P. Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: a population-based study from the National Prostate Cancer Register of Sweden. Scand J Urol Nephrol. 2010;44(6):384-90.
DOI: https://doi.org/10.3109/00365599.2010.498793
SwePub: urn:nbn:se:umu:diva-42219

Grundmark B, Garmo H, Zethelius B, Stattin P, Lambe M, Holmberg L. Anti-androgen prescribing patterns, patient treatment adherence and influencing factors; results from the nationwide PCBaSe Sweden. Eur J Clin Pharmacol. 2012;68(12):1619-30.
DOI: https://doi.org/10.1007/s00228-012-1290-x
SwePub: urn:nbn:se:umu:diva-62782

Wirén S, Stattin P. Forskning på kvalitetsregister ger klinisk nytta. Resultat från Nationella prostata­cancerregistret. [Research on quality registries provides clinical benefit. Results from the National Prostate Cancer Registry]. Läkartidningen. 2012;109(26-28):1294-7.
SwePub: urn:nbn:se:umu:diva-70195

Carlsson S, Sandin F, Fall K, Lambe M, Adolfsson J, Stattin P, et al. Risk of suicide in men with low-risk prostate cancer. Eur J Cancer. 2013;49(7):1588-99.
DOI: https://doi.org/10.1016/j.ejca.2012.12.018
SwePub: urn:nbn:se:oru:diva-29151

Bratt O, Carlsson S, Holmberg E, Holmberg L, Johansson E, Josefsson A, et al. The Study of Active Monitoring in Sweden (SAMS): a randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancer. Scand J Urol. 2013;47(5):347-55.
DOI: https://doi.org/10.3109/21681805.2013.813962
SwePub: urn:nbn:se:uu:diva-210941

Makarov DV, Loeb S, Ulmert D, Drevin L, Lambe M, Stattin P. Prostate cancer imaging trends after a nationwide effort to discourage inappropriate prostate cancer imaging. J Natl Cancer Inst. 2013;105(17):1306-13.
DOI: https://doi.org/10.1093/jnci/djt175
SwePub: urn:nbn:se:uu:diva-208651

Robinson D, Garmo H, Bill-Axelson A, Mucci L, Holmberg L, Stattin P. Use of 5α-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study. BMJ. 2013;346:f3406.
DOI: https://doi.org/10.1136/bmj.f3406
SwePub: urn:nbn:se:uu:diva-207267

Fall K, Garmo H, Gudbjörnsdottir S, Stattin P, Zethelius B. Diabetes mellitus and prostate cancer risk; a nationwide case-control study within PCBaSe Sweden. Cancer Epidemiol Biomarkers Prev. 2013;22(6):1102-9.
DOI: https://doi.org/10.1158/1055-9965.Epi-12-1046
SwePub: urn:nbn:se:oru:diva-32998

Lissbrant IF, Garmo H, Widmark A, Stattin P. Population-based study on use of chemotherapy in men with castration resistant prostate cancer. Acta Oncol. 2013;52(8):1593-601.
DOI: https://doi.org/10.3109/0284186x.2013.770164
SwePub: urn:nbn:se:uu:diva-210547

Loeb S, Drevin L, Robinson D, Holmberg E, Carlsson S, Lambe M, et al. Risk of localized and advanced prostate cancer among immigrants versus native-born Swedish men: a nation-wide population-based study. Cancer Causes Control. 2013;24(2):383-90.
DOI: https://doi.org/10.1007/s10552-012-0124-6
SwePub: urn:nbn:se:umu:diva-66780

Van Hemelrijck M, Garmo H, Holmberg L, Bill-Axelson A, Carlsson S, Akre O, et al. Thromboembolic events following surgery for prostate cancer. Eur Urol. 2013;63(2):354-63.
DOI: https://doi.org/10.1016/j.eururo.2012.09.041
SwePub: urn:nbn:se:umu:diva-66402

Wirén SM, Drevin LI, Carlsson SV, Akre O, Holmberg EC, Robinson DE, et al. Fatherhood status and risk of prostate cancer: nationwide, population-based case-control study. Int J Cancer. 2013;133(4):937-43.
DOI: https://doi.org/10.1002/ijc.28057
SwePub: urn:nbn:se:umu:diva-70196

Eloranta S, Adolfsson J, Lambert PC, Stattin P, Akre O, Andersson TM, et al. How can we make cancer survival statistics more useful for patients and clinicians: an illustration using localized prostate cancer in Sweden. Cancer Causes Control. 2013;24(3):505-15.
DOI: https://doi.org/10.1007/s10552-012-0141-5
SwePub: urn:nbn:se:umu:diva-67379

Rider JR, Sandin F, Andrén O, Wiklund P, Hugosson J, Stattin P. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. Eur Urol. 2013;63(1):88-96.
DOI: https://doi.org/10.1016/j.eururo.2012.08.001
SwePub: urn:nbn:se:oru:diva-56721

Stattin P, Loeb S. "To measure is to know. If you cannot measure it, you cannot improve it": statistical modeling cannot compensate for unmeasured bias. Eur Urol. 2014;65(4):701-3.
DOI: https://doi.org/10.1016/j.eururo.2013.06.037
SwePub: urn:nbn:se:umu:diva-87387

Nilsson H, Stranne J, Stattin P, Nordin P. Incidence of groin hernia repair after radical prostatectomy: a population-based nationwide study. Ann Surg. 2014;259(6):1223-7.
DOI: https://doi.org/10.1097/SLA.0b013e3182975c88
SwePub: urn:nbn:se:umu:diva-82944

Loeb S, Berglund A, Stattin P. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer. J Urol. 2013;190(5):1742-9.
DOI: https://doi.org/10.1016/j.juro.2013.05.054
SwePub: urn:nbn:se:uu:diva-210560

Lycken M, Garmo H, Adolfsson J, Stattin P, Holmberg L, Bill-Axelson A. Patterns of androgen deprivation therapies among men diagnosed with localised prostate cancer: a population-based study. Eur J Cancer. 2014;50(10):1789-98.
DOI: https://doi.org/10.1016/j.ejca.2014.03.279
SwePub: urn:nbn:se:uu:diva-228967

Ohmann EL, Loeb S, Robinson D, Bill-Axelson A, Berglund A, Stattin P. Nationwide, population-based study of prostate cancer stage migration between and within clinical risk categories. Scand J Urol. 2014;48(5):426-35.
DOI: https://doi.org/10.3109/21681805.2014.892150
SwePub: urn:nbn:se:uu:diva-235161

Sooriakumaran P, Nyberg T, Akre O, Haendler L, Heus I, Olsson M, et al. Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ. 2014;348:g1502.
DOI: https://doi.org/10.1136/bmj.g1502
SwePub: oai:gup.ub.gu.se/194778

Stattin P, Carlsson S, Holmström B, Vickers A, Hugosson J, Lilja H, et al. Prostate cancer mortality in areas with high and low prostate cancer incidence. J Natl Cancer Inst. 2014;106(3):dju007.
DOI: https://doi.org/10.1093/jnci/dju007
SwePub: oai:DiVA.org:uu-245647

Vellekoop A, Loeb S, Folkvaljon Y, Stattin P. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer. J Urol. 2014;191(2):350-7.
DOI: https://doi.org/10.1016/j.juro.2013.09.034
SwePub: oai:DiVA.org:uu-218937

Bonn SE, Wiklund F, Sjölander A, Szulkin R, Stattin P, Holmberg E, et al. Body mass index and weight change in men with prostate cancer: progression and mortality. Cancer Causes Control. 2014;25(8):933-43.
DOI: https://doi.org/10.1007/s10552-014-0393-3
SwePub: oai:DiVA.org:umu-91818

Bratt O, Drevin L, Akre O, Garmo H, Stattin P. Family history and probability of prostate cancer, differentiated by risk category: a nationwide population-based study. J Natl Cancer Inst. 2016;108(10).
DOI: https://doi.org/10.1093/jnci/djw110
SwePub: oai:DiVA.org:uu-310024

Loeb S, Folkvaljon Y, Makarov DV, Bratt O, Bill-Axelson A, Stattin P. Five-year nationwide follow-up study of active surveillance for prostate cancer. Eur Urol. 2015;67(2):233-8.
DOI: https://doi.org/10.1016/j.eururo.2014.06.010
SwePub: oai:DiVA.org:umu-99351

Stattin P, Vickers AJ, Sjoberg DD, Johansson R, Granfors T, Johansson M, et al. Improving the specificity of screening for lethal prostate cancer using prostate-specific antigen and a panel of kallikrein markers: a nested case-control study. Eur Urol. 2015;68(2):207-13.
DOI: https://doi.org/10.1016/j.eururo.2015.01.009
SwePub: oai:DiVA.org:umu-109383

Bratt O, Folkvaljon Y, Loeb S, Klotz L, Egevad L, Stattin P. Upper limit of cancer extent on biopsy defining very low-risk prostate cancer. BJU Int. 2015;116(2):213-9.
DOI: https://doi.org/10.1111/bju.12874
SwePub: oai:DiVA.org:uu-304587

Markt SC, Grotta A, Nyren O, Adami HO, Mucci LA, Valdimarsdottir UA, et al. Insufficient sleep and risk of prostate cancer in a large Swedish cohort. Sleep. 2015;38(9):1405-10.
DOI: https://doi.org/10.5665/sleep.4978
SwePub: oai:DiVA.org:umu-111158

Robinson D, Garmo H, Holmberg L, Stattin P. 5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer. Cancer Causes Control. 2015;26(9):1289-97. 10.1007/s10552-015-0622-4
DOI: https://doi.org/10.1007/s10552-015-0622-4
SwePub: oai:DiVA.org:umu-108454

Fridriksson JÖ, Gunseus K, Stattin P. Information on pros and cons of prostate-specific antigen testing to men prior to blood draw: a study from the National Prostate Cancer Register (NPCR) of Sweden. Scand J Urol Nephrol. 2012;46(5):326-31.
DOI: https://doi.org/10.3109/00365599.2012.691110
SwePub: urn:nbn:se:umu:diva-61185

Fridriksson JÖ, Holmberg E, Adolfsson J, Lambe M, Bill-Axelson A, Carlsson S, et al. Rehospitalization after radical prostatectomy in a nationwide, population based study. J Urol. 2014;192(1):112-9.
DOI: https://doi.org/10.1016/j.juro.2014.01.109
SwePub: oai:DiVA.org:umu-85907

Fridriksson JÖ, Folkvaljon Y, Nilsson P, Robinson D, Franck-Lissbrant I, Ehdaie B, et al. Long-term adverse effects after curative radiotherapy and radical prostatectomy: population-based nationwide register study. Scand J Urol. 2016;50(5):338-45.
DOI: https://doi.org/10.1080/21681805.2016.1194460
SwePub: oai:lup.lub.lu.se:0e9a611c-81d1-4514-b70a-fd2a8bc7cf2c

Van Hemelrijck M, Garmo H, Wigertz A, Nilsson P, Stattin P. Cohort profile update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base - a refined prostate cancer trajectory. Int J Epidemiol. 2016;45(1):73-82.
DOI: https://doi.org/10.1093/ije/dyv305
SwePub: oai:DiVA.org:umu-121492

Danneman D, Drevin L, Delahunt B, Samaratunga H, Robinson D, Bratt O, et al. Accuracy of prostate biopsies for predicting Gleason score in radical prostatectomy specimens: nationwide trends 2000-2012. BJU Int. 2017;119(1):50-6.
DOI: https://doi.org/10.1111/bju.13458
SwePub: oai:DiVA.org:umu-130217

Sooriakumaran P, Nyberg T, Akre O, Widmark A, Hamdy F, Graefen M, et al. Survival among men at high risk of disseminated prostate cancer receiving initial locally directed radical treatment or initial androgen deprivation therapy. Eur Urol. 2017;72(3):345-51.
DOI: https://doi.org/10.1016/j.eururo.2017.04.002
SwePub: oai:gup.ub.gu.se/259424

Stattin P, Sandin F, Thomsen FB, Garmo H, Robinson D, Lissbrant IF, et al. Association of radical local treatment with mortality in men with very high-risk prostate cancer: a semiecologic, nationwide, population-based study. Eur Urol. 2017;72(1):125-34.
DOI: https://doi.org/10.1016/j.eururo.2016.07.023
SwePub: oai:gup.ub.gu.se/255032

Thorstenson A, Garmo H, Adolfsson J, Bratt O. Cancer specific mortality in men diagnosed with prostate cancer before age 50 years: a nationwide population based study. J Urol. 2017;197(1):61-6.
DOI: https://doi.org/10.1016/j.juro.2016.06.080
SwePub: oai:lup.lub.lu.se:3f7c3a7c-e814-49c3-bfcf-ba5b4f6960a8

Van Hemelrijck M, Garmo H, Lindhagen L, Bratt O, Stattin P, Adolfsson J. Quantifying the transition from active surveillance to watchful waiting among men with very low-risk prostate cancer. Eur Urol. 2017;72(4):534-41.
DOI: https://doi.org/10.1016/j.eururo.2016.10.031
SwePub: oai:DiVA.org:uu-334734

Arthur R, Williams R, Garmo H, Holmberg L, Stattin P, Malmström H, et al. Serum inflammatory markers in relation to prostate cancer severity and death in the Swedish AMORIS study. Int J Cancer. 2018;142(11):2254-62.
DOI: https://doi.org/10.1002/ijc.31256
SwePub: oai:DiVA.org:uu-352560

Jan M, Bonn SE, Sjölander A, Wiklund F, Stattin P, Holmberg E, et al. The roles of stress and social support in prostate cancer mortality. Scand J Urol. 2016;50(1):47-55.
DOI: https://doi.org/10.3109/21681805.2015.1079796
SwePub: oai:DiVA.org:umu-114894

Loeb S, Folkvaljon Y, Robinson D, Lissbrant IF, Egevad L, Stattin P. Evaluation of the 2015 Gleason grade groups in a nationwide population-based cohort. Eur Urol. 2016;69(6):1135-41.
DOI: https://doi.org/10.1016/j.eururo.2015.11.036
SwePub: oai:DiVA.org:uu-302231

Loeb S, Folkvaljon Y, Robinson D, Makarov DV, Bratt O, Garmo H, et al. Immediate versus delayed prostatectomy: Nationwide population-based study. Scand J Urol. 2016;50(4):246-54.
DOI: https://doi.org/10.3109/21681805.2016.1166153
SwePub: oai:DiVA.org:uu-300103

Loeb S, Folkvaljon Y, Robinson D, Schlomm T, Garmo H, Stattin P. Phosphodiesterase type 5 inhibitor use and disease recurrence after prostate cancer treatment. Eur Urol. 2016;70(5):824-8.
DOI: https://doi.org/10.1016/j.eururo.2015.12.013
SwePub: oai:DiVA.org:umu-121204

Bosco C, Garmo H, Adolfsson J, Stattin P, Holmberg L, Nilsson P, et al. Prostate cancer radiation therapy and risk of thromboembolic events. Int J Radiat Oncol Biol Phys. 2017;97(5):1026-31.
DOI: https://doi.org/10.1016/j.ijrobp.2017.01.218
SwePub: LIBRIS-ID:oai:DiVA.org:uu-324345

Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelson A, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the population-based PCBaSe Sweden. J Clin Oncol. 2010;28(21):3448-56.
DOI: https://doi.org/10.1200/jco.2010.29.1567
SwePub: urn:nbn:se:umu:diva-42209

Bosco C, Wong C, Garmo H, Crawley D, Holmberg L, Hammar N, et al. Drugs for metabolic conditions and prostate cancer death in men on GnRH agonists. BJU Int. 2018;121(2):260-7.
DOI: https://doi.org/10.1111/bju.14023
SwePub: oai:DiVA.org:uu-336233

Carlsson J, Davidsson S, Fridfeldt J, Giunchi F, Fiano V, Grasso C, et al. Quantity and quality of nucleic acids extracted from archival formalin fixed paraffin embedded prostate biopsies. BMC Med Res Methodol. 2018;18(1):161.
DOI: https://doi.org/10.1186/s12874-018-0628-1
SwePub: oai:DiVA.org:oru-70618

Crawley D, Garmo H, Rudman S, Stattin P, Zethelius B, Armes J, et al. Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study. BMJ Open. 2018;8(3):e020787.
DOI: https://doi.org/10.1136/bmjopen-2017-020787
SwePub: oai:DiVA.org:uu-358574

Crawley D, Garmo H, Rudman S, Stattin P, Zethelius B, Holmberg L, et al. Association between type 2 diabetes, curative treatment and survival in men with intermediate- and high-risk localized prostate cancer. BJU Int. 2018;121(2):209-16.
DOI: https://doi.org/10.1111/bju.13880
SwePub: oai:DiVA.org:uu-336246

FitzGerald LM, Zhao S, Leonardson A, Geybels MS, Kolb S, Lin DW, et al. Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases. Prostate Cancer Prostatic Dis. 2018;21(2):228-37.
DOI: https://doi.org/10.1038/s41391-017-0029-2
SwePub: oai:DiVA.org:umu-150859

Franck Lissbrant I, Ventimiglia E, Robinson D, Törnblom M, Hjälm-Eriksson M, Lambe M, et al. Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden. Scand J Urol. 2018;52(2):143-50.
DOI: https://doi.org/10.1080/21681805.2018.1426039
SwePub: oai:gup.ub.gu.se/272178

Gnanapragasam VJ, Bratt O, Muir K, Lee LS, Huang HH, Stattin P, et al. The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study. BMC Med. 2018;16(1):31.
DOI: https://doi.org/10.1186/s12916-018-1019-5
SwePub: oai:DiVA.org:umu-146163

Häggström C, Van Hemelrijck M, Garmo H, Robinson D, Stattin P, Rowley M, et al. Heterogeneity in risk of prostate cancer: A Swedish population-based cohort study of competing risks and type 2 diabetes mellitus. Int J Cancer. 2018;143(8):1868-75.
DOI: https://doi.org/10.1002/ijc.31587
SwePub: oai:DiVA.org:umu-152192

Jansson F, Drevin L, Frisell T, Stattin P, Bratt O, Akre O. Concordance of non-low-risk disease among pairs of brothers with prostate cancer. J Clin Oncol. 2018;36(18):1847-52.
DOI: https://doi.org/10.1200/jco.2017.76.6907
SwePub: oai:gup.ub.gu.se/269432

Lycken M, Drevin L, Garmo H, Stattin P, Adolfsson J, Lissbrant IF, et al. The use of palliative medications before death from prostate cancer: Swedish population-based study with a comparative overview of European data. Eur J Cancer. 2018;88:101-8.
DOI: https://doi.org/10.1016/j.ejca.2017.10.023
SwePub: oai:gup.ub.gu.se/263317

Nugin H, Folkvaljon Y, Damber JE, Adolfsson J, Robinson D, Stattin P. Work-up and treatment of prostate cancer before and after publication of the first national guidelines on prostate cancer care in Sweden. Scand J Urol. 2018;52(4):277-84.
DOI: https://doi.org/10.1080/21681805.2018.1512650
SwePub: oai:DiVA.org:uu-373222

Robinson D, Garmo H, Lissbrant IF, Widmark A, Pettersson A, Gunnlaugsson A, et al. Prostate cancer death after radiotherapy or radical prostatectomy: a nationwide population-based observational study. Eur Urol. 2018;73(4):502-11.
DOI: https://doi.org/10.1016/j.eururo.2017.11.039
SwePub: oai:gup.ub.gu.se/266666

Russell B, Garmo H, Beckmann K, Stattin P, Adolfsson J, Van Hemelrijck M. A case-control study of lower urinary-tract infections, associated antibiotics and the risk of developing prostate cancer using PCBaSe 3.0. PLoS One. 2018;13(4):e0195690.
DOI: https://doi.org/10.1371/journal.pone.0195690
SwePub: oai:DiVA.org:uu-352474

Stattin P, Sandin F, Loeb S, Robinson D, Lissbrant IF, Lambe M. Public online reporting from a nationwide population-based clinical prostate cancer register. BJU Int. 2018;122(1):8-10.
DOI: https://doi.org/10.1111/bju.14213
SwePub: oai:gup.ub.gu.se/274909

Tomic K, Ventimiglia E, Robinson D, Häggström C, Lambe M, Stattin P. Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. Nationwide population-based study. Int J Cancer. 2018;142(12):2478-84.
DOI: https://doi.org/10.1002/ijc.31272
SwePub: oai:DiVA.org:umu-144548

Ventimiglia E, Folkvaljon Y, Carlsson S, Bratt O, Montorsi F, Volz D, et al. Nationwide, population-based study of post radical prostatectomy urinary incontinence correction surgery. J Surg Oncol. 2018;117(2):321-7.
DOI: https://doi.org/10.1002/jso.24816
SwePub: oai:DiVA.org:umu-145787

Arthur R, Møller H, Garmo H, Häggström C, Holmberg L, Stattin P, et al. Serum glucose, triglycerides, and cholesterol in relation to prostate cancer death in the Swedish AMORIS study. Cancer Causes Control. 2019;30(2):195-206.
DOI: https://doi.org/10.1007/s10552-018-1093-1
SwePub: oai:DiVA.org:umu-157598

Beckmann K, Garmo H, Adolfsson J, Bosco C, Johansson E, Robinson D, et al. Androgen deprivation therapies and changes in comorbidity: a comparison of gonadotropin-releasing hormone agonists and antiandrogen monotherapy as primary therapy in men with high-risk prostate cancer. Eur Urol. 2019;75(4):676-83.
DOI: https://doi.org/10.1016/j.eururo.2018.11.022
SwePub: oai:DiVA.org:uu-380435

Beckmann K, Russell B, Josephs D, Garmo H, Haggstrom C, Holmberg L, et al. Chronic inflammatory diseases, anti-inflammatory medications and risk of prostate cancer: a population-based case-control study. BMC Cancer. 2019;19(1):612.
DOI: https://doi.org/10.1186/s12885-019-5846-3
SwePub: oai:DiVA.org:umu-161512

Bergengren O, Garmo H, Bratt O, Holmberg L, Johansson E, Bill-Axelson A. Determinants for choosing and adhering to active surveillance for localised prostate cancer: a nationwide population-based study. BMJ Open. 2019;9(12):e033944.
DOI: https://doi.org/10.1136/bmjopen-2019-033944
SwePub: oai:gup.ub.gu.se/291363

Cazzaniga W, Garmo H, Robinson D, Holmberg L, Bill-Axelson A, Stattin P. Mortality after radical prostatectomy in a matched contemporary cohort in Sweden compared to the Scandinavian Prostate Cancer Group 4 (SPCG-4) study. BJU Int. 2019;123(3):421-8.
DOI: https://doi.org/10.1111/bju.14563
SwePub: oai:DiVA.org:uu-381179

Cazzaniga W, Ventimiglia E, Alfano M, Robinson D, Lissbrant IF, Carlsson S, et al. Mini review on the use of clinical cancer registers for prostate cancer: The National Prostate Cancer Register (NPCR) of Sweden. Front Med (Lausanne). 2019;6:51.
DOI: https://doi.org/10.3389/fmed.2019.00051
SwePub: oai:gup.ub.gu.se/279498

Godtman RA, Månsson M, Bratt O, Robinsson D, Johansson E, Stattin P, et al. Development and validation of a prediction model for identifying men with intermediate- or high-risk prostate cancer for whom bone imaging is unnecessary: a nation-wide population-based study. Scand J Urol. 2019;53(6):378-84.
DOI: https://doi.org/10.1080/21681805.2019.1697358
SwePub: oai:gup.ub.gu.se/288020

Sverrisson I, Folkvaljon F, Chabok A, Stattin P, Smedh K, Nikberg M. Anastomotic leakage after anterior resection in patients with rectal cancer previously irradiated for prostate cancer. Eur J Surg Oncol. 2019;45(3):341-6.
DOI: https://doi.org/10.1016/j.ejso.2018.11.015
SwePub: oai:DiVA.org:uu-381093

Thomsen FB, Bosco C, Garmo H, Adolfsson J, Hammar N, Stattin P, et al. Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study. Acta Oncol. 2019;58(1):110-8.
DOI: https://doi.org/10.1080/0284186x.2018.1529427
SwePub: oai:DiVA.org:uu-379242

Zelic R, Zugna D, Bottai M, Andrén O, Fridfeldt J, Carlsson J, et al. Estimation of relative and absolute risks in a competing-risks setting using a nested case-control study design: Example from the ProMort study. Am J Epidemiol. 2019;188(6):1165-73.
DOI: https://doi.org/10.1093/aje/kwz026
SwePub: oai:DiVA.org:oru-75236

Ventimiglia E, Van Hemelrijck M, Lindhagen L, Stattin P, Garmo H. How to measure temporal changes in care pathways for chronic diseases using health care registry data. BMC Med Inform Decis Mak. 2019;19(1):103.
DOI: https://doi.org/10.1186/s12911-019-0823-y
SwePub: oai:DiVA.org:uu-386444

Aly M, Leval A, Schain F, Liwing J, Lawson J, Vágó E, et al. Survival in patients diagnosed with castration-resistant prostate cancer: a population-based observational study in Sweden. Scand J Urol. 2020;54(2):115-21.
DOI: https://doi.org/10.1080/21681805.2020.1739139
SwePub: oai:prod.swepub.kib.ki.se:143474491

Beckmann K, Garmo H, Lindahl B, Holmberg L, Stattin P, Adolfsson J, et al. Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study. Prostate Cancer Prostatic Dis. 2020;23(3):527-33.
DOI: https://doi.org/10.1038/s41391-020-0220-8
SwePub: oai:DiVA.org:uu-423872

Beckmann K, Garmo H, Nilsson P, Franck Lissbrant I, Widmark A, Stattin P. Radical radiotherapy for prostate cancer: patterns of care in Sweden 1998-2016. Acta Oncol. 2020;59(5):549-57.
DOI: https://doi.org/10.1080/0284186x.2020.1730003
SwePub: oai:DiVA.org:uu-423875

Crump C, Stattin P, Brooks JD, Stocks T, Sundquist J, Sieh W, et al. Early-life cardiorespiratory fitness and long-term risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2020;29(11):2187-94.
DOI: https://doi.org/10.1158/1055-9965.Epi-20-0535
SwePub: oai:DiVA.org:uu-428992

Franck Lissbrant I, Hjälm Eriksson M, Lambe M, Törnblom M, Stattin P. Set-up and preliminary results from the Patient-overview Prostate Cancer. Longitudinal registration of treatment of advanced prostate cancer in the National Prostate Cancer Register of Sweden. Scand J Urol. 2020;54(3):227-34.
DOI: https://doi.org/10.1080/21681805.2020.1756402
SwePub: oai:DiVA.org:uu-423801

Gedeborg R, Garmo H, Robinson D, Stattin P. Prescription-based prediction of baseline mortality risk among older men. PLoS One. 2020;15(10):e0241439.
DOI: https://doi.org/10.1371/journal.pone.0241439
SwePub: oai:DiVA.org:uu-429986

George G, Garmo H, Rudman S, Holmberg L, Robinson D, Stattin P, et al. Long-term adherence to GnRH agonists in men with prostate cancer. A nation-wide population-based study in Prostate Cancer data Base Sweden. Scand J Urol. 2020;54(1):20-6.
DOI: https://doi.org/10.1080/21681805.2019.1702093
SwePub: oai:DiVA.org:uu-406282

Jansson F, Folkvaljon F, Stattin P, Bratt O, Akre O. Risk of postoperative up staging or upgrading among men with low risk familial prostate cancer. J Urol. 2020;204(1):79-81.
DOI: https://doi.org/10.1097/ju.0000000000000793
SwePub: oai:gup.ub.gu.se/295138

Jochems SHJ, Stattin P, Häggström C, Järvholm B, Orho-Melander M, Wood AM, et al. Height, body mass index and prostate cancer risk and mortality by way of detection and cancer risk category. Int J Cancer. 2020;147(12):3328-38.
DOI: https://doi.org/10.1002/ijc.33150
SwePub: oai:DiVA.org:umu-172173

Lin E, Garmo H, Van Hemelrijck M, Adolfsson J, Stattin P, Zethelius B, et al. Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study. BMC Cancer. 2020;20(1):551.
DOI: https://doi.org/10.1186/s12885-020-07036-4
SwePub: oai:DiVA.org:uu-420205

Loeb S, Cazzaniga W, Robinson D, Garmo H, Stattin P. Opioid use after radical prostatectomy: nationwide, population based study in Sweden. J Urol. 2020;203(1):145-50.
DOI: https://doi.org/10.1097/ju.0000000000000451
SwePub: oai:DiVA.org:uu-406002

Lycken M, Drevin L, Garmo H, Larsson A, Andrén O, Holmberg L, et al. Adherence to guidelines for androgen deprivation therapy after radical prostatectomy: Swedish population-based study. Scand J Urol. 2020;54(3):208-14.
DOI: https://doi.org/10.1080/21681805.2020.1750475
SwePub: oai:DiVA.org:oru-81456

Mehtälä J, Zong J, Vassilev Z, Brobert G, Gabarró MS, Stattin P, et al. Overall survival and second primary malignancies in men with metastatic prostate cancer. PLoS One. 2020;15(2):e0227552.
DOI: https://doi.org/10.1371/journal.pone.0227552
SwePub: oai:DiVA.org:uu-413915

Orrason AW, Westerberg M, Garmo H, Lissbrant IF, Robinson D, Stattin P. Changes in treatment and mortality in men with locally advanced prostate cancer between 2000 and 2016: a nationwide, population-based study in Sweden. BJU Int. 2020;126(1):142-51.
DOI: https://doi.org/10.1111/bju.15077
SwePub: oai:gup.ub.gu.se/296771

Parker J, Crawley D, Garmo H, Lindahl B, Styrke J, Adolfsson J, et al. Use of warfarin or direct oral anticoagulants and risk of prostate cancer in PCBaSe: a nationwide case-control study. Front Oncol. 2020;10:571838.
DOI: https://doi.org/10.3389/fonc.2020.571838
SwePub: oai:DiVA.org:umu-176488

Pettersson A, Alm D, Garmo H, Hjelm Eriksson M, Castellanos E, Åström L, et al. Comparative effectiveness of different radical radiotherapy treatment regimens for prostate cancer: a population-based cohort study. JNCI Cancer Spectr. 2020;4(2):pkaa006.
DOI: https://doi.org/10.1093/jncics/pkaa006
SwePub: oai:gup.ub.gu.se/299063

Plym A, Clements M, Voss M, Holmberg L, Stattin P, Lambe M. Duration of sick leave after active surveillance, surgery or radiotherapy for localised prostate cancer: a nationwide cohort study. BMJ Open. 2020;10(3):e032914.
DOI: https://doi.org/10.1136/bmjopen-2019-032914
SwePub: oai:DiVA.org:uu-411316

Stranne J, Axen E, Franck-Lissbrant I, Fransson P, Frånlund M, Hugosson J, et al. Single institution followed by national implementation of systematic surgical quality control and feedback for radical prostatectomy: a 20-year journey. World J Urol. 2020;38(6):1397-411.
DOI: https://doi.org/10.1007/s00345-019-02887-4
SwePub: oai:gup.ub.gu.se/285911

Thomsen FB, Westerberg M, Garmo H, Robinson D, Holmberg L, Ulmert HD, et al. Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason grade: nationwide, population-based register study. PLoS One. 2020;15(1):e0228447.
DOI: https://doi.org/10.1371/journal.pone.0228447
SwePub: oai:DiVA.org:uu-413453

Thurtle D, Bratt O, Stattin P, Pharoah P, Gnanapragasam V. Comparative performance and external validation of the multivariable PREDICT prostate tool for non-metastatic prostate cancer: a study in 69,206 men from Prostate Cancer data Base Sweden (PCBaSe). BMC Med. 2020;18(1):139.
DOI: https://doi.org/10.1186/s12916-020-01606-w
SwePub: oai:gup.ub.gu.se/294862

Westerberg M, Franck Lissbrant I, Damber JE, Robinson D, Garmo H, Stattin P. Temporal changes in survival in men with de novo metastatic prostate cancer: nationwide population-based study. Acta Oncol. 2020;59(1):106-11.
DOI: https://doi.org/10.1080/0284186x.2019.1662084
SwePub: oai:gup.ub.gu.se/284520

Zelic R, Garmo H, Zugna D, Stattin P, Richiardi L, Akre O, et al. Predicting prostate cancer death with different pretreatment risk stratification tools: a head-to-head comparison in a nationwide cohort study. Eur Urol. 2020;77(2):180-8.
DOI: https://doi.org/10.1016/j.eururo.2019.09.027
SwePub: oai:DiVA.org:uu-405337

Beckmann K, Garmo H, Franck Lissbrant I, Stattin P. The value of real-world data in understanding prostate cancer risk and improving clinical care: examples from Swedish registries. Cancers (Basel). 2021;13(4).
DOI: https://doi.org/10.3390/cancers13040875
SwePub: oai:DiVA.org:uu-441121

Bergengren O, Westerberg M, Holmberg L, Stattin P, Bill-Axelson A, Garmo H. Variation in prostate-specific antigen testing rates and prostate cancer treatments and outcomes in a national 20-year cohort. JAMA Netw Open. 2021;4(5):e219444.
DOI: https://doi.org/10.1001/jamanetworkopen.2021.9444
SwePub: oai:DiVA.org:uu-444389

Fallara G, Alverbratt C, Garmo H, Vikman H, Hjelm Eriksson M, Lissbrant IF, et al. Time on treatment with abiraterone and enzalutamide in the Patient-overview Prostate Cancer in The National Prostate Cancer Register of Sweden. Acta Oncol. 2021;60(12):1589-96.
DOI: https://doi.org/10.1080/0284186x.2021.1978539
SwePub: oai:gup.ub.gu.se/309212

Fallara G, Gedeborg R, Bill-Axelson A, Garmo H, Stattin P. A drug comorbidity index to predict mortality in men with castration resistant prostate cancer. PLoS One. 2021;16(7):e0255239.
DOI: https://doi.org/10.1371/journal.pone.0255239
SwePub: oai:DiVA.org:uu-453480

Fallara G, Lissbrant IF, Styrke J, Montorsi F, Gedeborg R, Sandin F, et al. Rapid ascertainment of uptake of a new indication for abiraterone by use of three nationwide health care registries in Sweden. Acta Oncol. 2021;60(1):56-60.
DOI: https://doi.org/10.1080/0284186x.2020.1847321
SwePub: oai:DiVA.org:umu-178158

Fallara G, Sandin F, Styrke J, Carlsson S, Lissbrant IF, Ahlgren J, et al. Prostate cancer diagnosis, staging, and treatment in Sweden during the first phase of the COVID-19 pandemic. Scand J Urol. 2021;55(3):184-91.
DOI: https://doi.org/10.1080/21681805.2021.1910341
SwePub: oai:gup.ub.gu.se/305085

Gedeborg R, Styrke J, Loeb S, Garmo H, Stattin P. Androgen deprivation therapy and excess mortality in men with prostate cancer during the initial phase of the COVID-19 pandemic. PLoS One. 2021;16(10):e0255966.
DOI: https://doi.org/10.1371/journal.pone.0255966
SwePub: oai:DiVA.org:uu-460911

Gedeborg R, Sund M, Lambe M, Plym A, Fredriksson I, Syrjä J, et al. An aggregated comorbidity measure based on history of filled drug prescriptions: development and evaluation in two separate cohorts. Epidemiology. 2021;32(4):607-15.
DOI: https://doi.org/10.1097/ede.0000000000001358
SwePub: oai:DiVA.org:uu-449149

George G, Vikman H, Gedeborg R, Lissbrant IF, Garmo H, Styrke J, et al. Risk of cardiovascular events in men on abiraterone or enzalutamide combined with GnRH agonists: nation-wide, population-based cohort study in Sweden. Acta Oncol. 2021;60(4):459-65.
DOI: https://doi.org/10.1080/0284186x.2021.1885058
SwePub: oai:gup.ub.gu.se/302680

Godtman RA, Persson E, Cazzaniga W, Sandin F, Carlsson S, Ahlgren G, et al. Association of surgeon and hospital volume with short-term outcomes after robot-assisted radical prostatectomy: nationwide, population-based study. PLoS One. 2021;16(6):e0253081.
DOI: https://doi.org/10.1371/journal.pone.0253081
SwePub: oai:gup.ub.gu.se/306221

Hermann M, Vikman H, Stattin P, Katawazai A, Gustafsson O, Styrke J, et al. Androgen deprivation therapy and the risk for inguinal hernia: an observational nested case control study. Am J Mens Health. 2021;15(6):15579883211058606.
DOI: https://doi.org/10.1177/15579883211058606
SwePub: oai:DiVA.org:oru-96241

Lin E, Garmo H, Van Hemelrijck M, Adolfsson J, Stattin P, Zethelius B, et al. Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study. BMC Cancer. 2021;21(1):1259.
DOI: https://doi.org/10.1186/s12885-021-08941-y
SwePub: oai:DiVA.org:uu-460220

Lundström KJ, Garmo H, Gedeborg R, Stattin P, Styrke J. Short-term ciprofloxacin prophylaxis for prostate biopsy and risk of aortic aneurysm. Nationwide, population-based cohort study. Scand J Urol. 2021;55(3):221-6.
DOI: https://doi.org/10.1080/21681805.2021.1916072
SwePub: oai:DiVA.org:umu-183575

Orrason AW, Garmo H, Styrke J, Dickman PW, Stattin P. Comparison of relative survival and cause-specific survival in men with prostate cancer according to age and risk category: a nationwide, population-based study. Am J Epidemiol. 2021;190(10):2053-63.
DOI: https://doi.org/10.1093/aje/kwab146
SwePub: oai:DiVA.org:umu-189399

Shore R, Yu J, Ye W, Lagergren J, Rutegård M, Akre O, et al. Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer. Sci Rep. 2021;11(1):13486.
DOI: https://doi.org/10.1038/s41598-021-92347-0
SwePub: oai:DiVA.org:umu-185639

Svensson J, Lissbrant IF, Gauffin O, Hjälm-Eriksson M, Kilany S, Fagerlund K, et al. Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden. Scand J Urol. 2021;55(1):1-8.
DOI: https://doi.org/10.1080/21681805.2020.1851762
SwePub: oai:gup.ub.gu.se/300926

Westerberg M, Larsson R, Holmberg L, Stattin P, Garmo H. Simulation model of disease incidence driven by diagnostic activity. Stat Med. 2021;40(5):1172-88.
DOI: https://doi.org/10.1002/sim.8833
SwePub: oai:DiVA.org:uu-469809

Jochems SHJ, Fritz J, Häggström C, Stattin P, Stocks T. Prediagnostic markers of insulin resistance and prostate cancer risk and death: a pooled study. Cancer Med. 2023;12(12):13732-44.
DOI: https://doi.org/10.1002/cam4.6004
SwePub: oai:DiVA.org:uu-511763

Alverbratt C, Vikman H, Hjälm Eriksson M, Stattin P, Franck Lissbrant I. Time difference in retrieving clinical information in Patient-overview Prostate Cancer compared to electronic health records. Scand J Urol. 2022;56(2):95-101.
DOI: https://doi.org/10.1080/21681805.2021.2014561
SwePub: oai:gup.ub.gu.se/314226

Arnsrud Godtman R, Persson E, Bergengren O, Carlsson S, Johansson E, Robinsson D, et al. Surgeon volume and patient-reported urinary incontinence after radical prostatectomy. Population-based register study in Sweden. Scand J Urol. 2022;56(5-6):343-50.
DOI: https://doi.org/10.1080/21681805.2022.2119270
SwePub: oai:gup.ub.gu.se/322102

Balabanova Y, Farahmand B, Garmo H, Stattin P, Brobert G. Risk of venous thromboembolism in men with prostate cancer compared with men in the general population: a nationwide population-based cohort study in Sweden. BMJ Open. 2022;12(5):e055485.
DOI: https://doi.org/10.1136/bmjopen-2021-055485
SwePub: oai:DiVA.org:uu-477725

Balabanova Y, Farahmand B, Stattin P, Garmo H, Brobert G. Population-based study of long-term anticoagulation for treatment and secondary prophylaxis of venous thromboembolism in men with prostate cancer in Sweden. BMC Urol. 2022;22(1):15.
DOI: https://doi.org/10.1186/s12894-022-00967-z
SwePub: oai:DiVA.org:uu-467399

Björklund J, Stattin P, Rönmark E, Aly M, Akre O. The 90-day cause-specific mortality after radical prostatectomy: a nationwide population-based study. BJU Int. 2022;129(3):318-24.
DOI: https://doi.org/10.1111/bju.15533
SwePub: oai:DiVA.org:uu-459354

Bonde TM, Westerberg M, Aly M, Eklund M, Adolfsson J, Bill-Axelson A, et al. Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists. Scand J Urol. 2022;56(3):169-75.
DOI: https://doi.org/10.1080/21681805.2022.2070275
SwePub: oai:DiVA.org:uu-474430

Braide K, Kindblom J, Thellenberg Karlsson C, Stattin P, Hugosson J, Månsson M. Risk of severe late toxicity after radiotherapy following radical prostatectomy - a nationwide study. BJU Int. 2022;130(6):799-808.
DOI: https://doi.org/10.1111/bju.15769
SwePub: oai:gup.ub.gu.se/319221

Gedeborg R, Garmo H, Thellenberg-Karlsson C, Fallara G, Styrke J, Franck Lissbrant I, et al. Time on treatment with abiraterone in men with de novo metastatic castration sensitive prostate cancer: a drug utilization study. Acta Oncol. 2022;61(3):328-32.
DOI: https://doi.org/10.1080/0284186x.2021.2023215
SwePub: oai:gup.ub.gu.se/322455

Gedeborg R, Lindhagen L, Loeb S, Styrke J, Garmo H, Stattin P. Androgen deprivation therapy, comorbidity, cancer stage and mortality from COVID-19 in men with prostate cancer. Scand J Urol. 2022;56(2):104-11.
DOI: https://doi.org/10.1080/21681805.2021.2019304
SwePub: oai:DiVA.org:umu-190754

Jochems SHJ, Häggström C, Stattin P, Järvholm B, Stocks T. Association of blood pressure with prostate cancer risk by disease severity and prostate cancer death: a pooled cohort study. Cancer Epidemiol Biomarkers Prev. 2022;31(7):1483-91.
DOI: https://doi.org/10.1158/1055-9965.Epi-22-0159
SwePub: oai:DiVA.org:umu-198223

Jochems SHJ, Stattin P, Stocks T. Reply to Paulius Bosas, Gintaras Zaleskis, and Dainius Characiejus's Letter to the Editor re: Sylvia H.J. Jochems, Josef Fritz, Christel Häggström, Bengt Järvholm, Pär Stattin, Tanja Stocks. Smoking and risk of prostate cancer and prostate cancer death: a pooled study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.033. Therapeutic monitoring in prostate cancer should involve a cotinine test in current smokers: smoking cessation remains a cornerstone in preventive health care overall and for men with prostate cancer. Eur Urol. 2022;82(4):e115.
DOI: https://doi.org/10.1016/j.eururo.2022.07.005
SwePub: oai:lup.lub.lu.se:a0abcc69-6e31-4111-9181-4e260206cc67

Lin E, Garmo H, Van Hemelrijck M, Zethelius B, Stattin P, Hagström E, et al. Association of gonadotropin-releasing hormone agonists for prostate cancer with cardiovascular disease risk and hypertension in men with diabetes. JAMA Netw Open. 2022;5(8):e2225600.
DOI: https://doi.org/10.1001/jamanetworkopen.2022.25600
SwePub: oai:DiVA.org:uu-482672

Orrason AW, Westerberg M, Albertsen P, Styrke J, Robinson D, Garmo H, et al. Diagnostic activity impacts lifetime risk of prostate cancer diagnosis more strongly than life expectancy. PLoS One. 2022;17(11):e0277784.
DOI: https://doi.org/10.1371/journal.pone.0277784
SwePub: oai:DiVA.org:uu-471669

Stattin P. Editorial comment to 'Swedish National Guidelines on prostate cancer part I and II' by Bratt et al. How to survey adherence to guidelines by use of clinical cancer registers. Scand J Urol. 2022;56(4):285-6.
DOI: https://doi.org/10.1080/21681805.2022.2107069
SwePub: oai:DiVA.org:uu-489380

Stenman C, Abrahamsson E, Redsäter M, Gnanapragasam VJ, Bratt O. Rates of positive abdominal computed tomography and bone scan findings among men with Cambridge Prognostic Group 4 or 5 prostate cancer: a nationwide registry study. Eur Urol Open Sci. 2022;41:123-5.
DOI: https://doi.org/10.1016/j.euros.2022.05.007
SwePub: oai:gup.ub.gu.se/319151

Van Hemelrijck M, Ventimiglia E, Robinson D, Gedeborg R, Holmberg L, Stattin P, et al. Population-based estimates of age and comorbidity specific life expectancy: a first application in Swedish males. BMC Med Inform Decis Mak. 2022;22(1):35.
DOI: https://doi.org/10.1186/s12911-022-01766-0
SwePub: oai:DiVA.org:uu-468382

Ventimiglia E, Bill-Axelson A, Adolfsson J, Aly M, Eklund M, Westerberg M, et al. Modeling disease trajectories for castration-resistant prostate cancer using nationwide population-based data. Eur Urol Open Sci. 2022;44:46-51.
DOI: https://doi.org/10.1016/j.euros.2022.07.010
SwePub: oai:DiVA.org:uu-486335

Ventimiglia E, Bill-Axelson A, Bratt O, Montorsi F, Stattin P, Garmo H. Long-term outcomes among men undergoing active surveillance for prostate cancer in Sweden. JAMA Netw Open. 2022;5(9):e2231015.
DOI: https://doi.org/10.1001/jamanetworkopen.2022.31015
SwePub: oai:gup.ub.gu.se/321610

Ahlberg MS, Garmo H, Holmberg L, Bill-Axelson A. Variations in the uptake of active surveillance for prostate cancer and its impact on outcomes. Eur Urol Open Sci. 2023;52:166-73.
DOI: https://doi.org/10.1016/j.euros.2023.04.006
SwePub: oai:DiVA.org:uu-509996

Bonde TM, Garmo H, Stattin P, Nilsson P, Gunnlaugsson A, Swanberg D, et al. Risk of prostate cancer death after radical radiotherapy with neoadjuvant and adjuvant therapy with bicalutamide or gonadotropin-releasing hormone agonists. Acta Oncol. 2023;62(12):1815-21.
DOI: https://doi.org/10.1080/0284186x.2023.2269600
SwePub: oai:DiVA.org:uu-523223

Corsini C, Garmo H, Orrason AW, Gedeborg R, Stattin P, Westerberg M. Survival trend in individuals with de novo metastatic prostate cancer after the introduction of doublet therapy. JAMA Netw Open. 2023;6(10):e2336604.
DOI: https://doi.org/10.1001/jamanetworkopen.2023.36604
SwePub: oai:DiVA.org:uu-514508

Crump C, Stattin P, Brooks JD, Sundquist J, Bill-Axelson A, Edwards AC, et al. Long-term risks of depression and suicide among men with prostate cancer: a national cohort study. Eur Urol. 2023;84(3):263-72.
DOI: https://doi.org/10.1016/j.eururo.2023.04.026
SwePub: oai:DiVA.org:uu-512857

Crump C, Stattin P, Brooks JD, Sundquist J, Edwards AC, Sieh W, et al. Risks of alcohol and drug use disorders in prostate cancer survivors: a national cohort study. JNCI Cancer Spectr. 2023;7(4).
DOI: https://doi.org/10.1093/jncics/pkad046
SwePub: oai:DiVA.org:uu-509286

Garcia-Albeniz X, Stattin P, Westerberg M, Weinrib R, Sandstrom P, Vassilev Z. Design considerations for observational studies of drugs for advanced cancer. Pharmacoepidemiol Drug Saf. 2023;32(7):812-5.
DOI: https://doi.org/10.1002/pds.5612
SwePub: oai:DiVA.org:uu-507636

Gedeborg R, Sandin F, Thellenberg-Karlsson C, Styrke J, Franck Lissbrant I, Garmo H, et al. Uptake of doublet therapy for de novo metastatic castration sensitive prostate cancer: a population-based drug utilisation study in Sweden. Scand J Urol. 2023;58.
DOI: https://doi.org/10.2340/sju.v58.9572
SwePub: oai:DiVA.org:uu-524282

George G, Garmo H, Adolfsson J, Elf K, Gedeborg R, Holmberg L, et al. Use of antiepileptic drugs and risk of prostate cancer: a nationwide case-control study in Prostate Cancer data Base Sweden. J Oncol. 2023;2023:9527920.
DOI: https://doi.org/10.1155/2023/9527920
SwePub: oai:DiVA.org:uu-514507

Lin E, Garmo H, Hagström E, Van Hemelrijck M, Adolfsson J, Stattin P, et al. Association between atherogenic lipids and GnRH agonists for prostate cancer in men with T2DM: a nationwide, population-based cohort study in Sweden. Br J Cancer. 2023;128(5):814-24.
DOI: https://doi.org/10.1038/s41416-022-02091-z
SwePub: oai:DiVA.org:uu-491313

Robinson D, Abdulkareem R, Nasrollah D, Ljung A, Hintze P, Wallby S, et al. Frequency of biopsy and tumor grade before vs after introduction of prostate magnetic resonance imaging. JAMA Netw Open. 2023;6(8):e2330233.
DOI: https://doi.org/10.1001/jamanetworkopen.2023.30233
SwePub: oai:DiVA.org:umu-214053

Shore R, Zhang J, Ye W, Stattin P, Lindblad M. Risk of colorectal adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer; a nationwide cohort study. Cancer Causes Control. 2023;34(11):949-61.
DOI: https://doi.org/10.1007/s10552-023-01736-5
SwePub: oai:DiVA.org:uu-514510

Stattin P, Westerberg M, Lissbrant IF, Eriksson MH, Kjellman A, Ullén A, et al. Real world outcomes in patients with metastatic, castration-resistant prostate cancer treated with radium-223 in routine clinical practice in Sweden. Clin Genitourin Cancer. 2023;21(1):107.e1-.e9.
DOI: https://doi.org/10.1016/j.clgc.2022.09.002
SwePub: oai:DiVA.org:uu-492640

Sun M, Fritz J, Häggström C, Bjørge T, Nagel G, Manjer J, et al. Metabolically (un)healthy obesity and risk of obesity-related cancers: a pooled study. J Natl Cancer Inst. 2023;115(4):456-67.
DOI: https://doi.org/10.1093/jnci/djad008
SwePub: oai:DiVA.org:umu-211797

Westerberg M, Beckmann K, Gedeborg R, Irenaeus S, Holmberg L, Garmo H, et al. Choice of imputation method for missing metastatic status affected estimates of metastatic prostate cancer incidence. J Clin Epidemiol. 2023;155:22-30.
DOI: https://doi.org/10.1016/j.jclinepi.2022.12.008
SwePub: oai:DiVA.org:uu-492637

Ahlberg M, Garmo H, Stattin P, Gedeborg R, Edlund C, Holmberg L, et al. Triggers for transition from active surveillance to radical treatment of prostate cancer 2008-2020 - a case-control study. Scand J Urol. 2024;59:63-9.
DOI: https://doi.org/10.2340/sju.v59.34803
SwePub: oai:DiVA.org:uu-515871

Corsini C, Bergengren O, Carlsson S, Garmo H, Hjelm-Eriksson M, Fransson P, et al. Patient-reported side effects 1 year after radical prostatectomy or radiotherapy for prostate cancer: a register-based nationwide study. Eur Urol Oncol. 2024;7(3):605-13.
DOI: https://doi.org/10.1016/j.euo.2023.12.007
SwePub: oai:DiVA.org:uu-533106

Crump C, Stattin P, Brooks JD, Sundquist J, Edwards AC, Sundquist K, et al. Risks of depression, anxiety, and suicide in partners of men with prostate cancer: a national cohort study. J Natl Cancer Inst. 2024;116(5):745-52.
DOI: https://doi.org/10.1093/jnci/djad257
SwePub: oai:lup.lub.lu.se:b19cc7e9-17a4-4a3e-b4f4-f4b52fad3739

Crump C, Stattin P, Brooks JD, Sundquist J, Sieh W, Sundquist K. Mortality risks associated with depression in men with prostate cancer. Eur Urol Oncol. 2024;S2588-9311(24)00089-0.
DOI: https://doi.org/10.1016/j.euo.2024.03.012

Egevad L, Micoli C, Delahunt B, Samaratunga H, Orrason AW, Garmo H, et al. Prognosis of Gleason score 8 prostatic adenocarcinoma in needle biopsies: a nationwide population-based study. Virchows Arch. 2024;484(6):995-1003.
DOI: https://doi.org/10.1007/s00428-024-03810-y
SwePub: oai:prod.swepub.kib.ki.se:238683251

Egevad L, Micoli C, Samaratunga H, Delahunt B, Garmo H, Stattin P, et al. Prognosis of Gleason score 9-10 prostatic adenocarcinoma in needle biopsies: a nationwide population-based study. Eur Urol Oncol. 2024;7(2):213-21.
DOI: https://doi.org/10.1016/j.euo.2023.11.002
SwePub: oai:prod.swepub.kib.ki.se:237978024

Franck Lissbrant I, Styrke J, Törnblom M, Hjelm Eriksson M, Axén E, Stattin P. Prostatacancerregistret – för patienter, sjukvård och forskning. Läkartidningen. 2024;121:23196.

Fritz J, Jochems SHJ, Bjørge T, Wood AM, Häggström C, Ulmer H, et al. Body mass index, triglyceride-glucose index, and prostate cancer death: a mediation analysis in eight European cohorts. Br J Cancer. 2024;130(2):308-16.
DOI: https://doi.org/10.1038/s41416-023-02526-1
SwePub: oai:DiVA.org:uu-531609

Lundberg F, Robinson D, Bratt O, Fallara G, Lambe M, Johansson ALV. Time trends in the use of curative treatment in men 70 years and older with nonmetastatic prostate cancer. Acta Oncol. 2024;63:95-104.
DOI: https://doi.org/10.2340/1651-226x.2024.26189
SwePub: oai:prod.swepub.kib.ki.se:238505996

Scilipoti P, Liedberg F, Garmo H, Wilberg Orrason A, Stattin P, Westerberg M. Risk of prostate cancer death in men diagnosed with prostate cancer at cystoprostatectomy. A nationwide population-based study. Scand J Urol. 2024;59:98-103.
DOI: https://doi.org/10.2340/sju.v59.40001
SwePub: oai:DiVA.org:uu-534084

Stattin P, Fleming S, Lin X, Lefresne F, Brookman-May SD, Mundle SD, et al. Population-based study of disease trajectory after radical treatment for high-risk prostate cancer. BJU Int. 2024;134(1):96-102.
DOI: https://doi.org/10.1111/bju.16362
SwePub: oai:DiVA.org:umu-224254

Strömberg U, Berglund A, Carlsson S, Thellenberg Karlsson C, Lambe M, Lissbrant IF, et al. Socioeconomic inequality in prostate cancer diagnostics, primary treatment, rehabilitation, and mortality in Sweden. Int J Cancer. 2024;155(4):637-45.
DOI: https://doi.org/10.1002/ijc.34932
SwePub: oai:gup.ub.gu.se/336383

Thomsen FF, Garmo H, Egevad L, Stattin P, Brasso K. Temporal trend in risk of prostate cancer death in men with favourable-risk prostate cancer. Scand J Urol. 2024;59:76-83.
DOI: https://doi.org/10.2340/sju.v59.34015
SwePub: oai:DiVA.org:uu-530586

Westerberg M, Garmo H, Robinson D, Stattin P, Gedeborg R. Target trial emulation using new comorbidity indices provided risk estimates comparable to a randomized trial. J Clin Epidemiol. 2024;174:111504.
DOI: https://doi.org/10.1016/j.jclinepi.2024.111504
SwePub: oai:DiVA.org:uu-540054

Westerberg M, Irenaeus S, Garmo H, Stattin P, Gedeborg R. Development and validation of a multi-dimensional diagnosis-based comorbidity index that improves prediction of death in men with prostate cancer: nationwide, population-based register study. PLoS One. 2024;19(1):e0296804.
DOI: https://doi.org/10.1371/journal.pone.0296804
SwePub: oai:DiVA.org:uu-526555